Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | CCR5 | P51681 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853362 | 1.00 | MEN1 (0.52) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL4201992 | 0.80 | CCR5 (0.53) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL13853361 | 0.80 | OPRM1 (0.60) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL13853364 | 0.80 | CCR5 (0.53) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL4201650 | 0.80 | OPRM1 (0.60) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL13853360 | 0.80 | OPRM1 (0.53) | MEN1KMT2AOPRM1CCR5HTT | |
| SCHEMBL4197879 | 0.80 | OPRM1 (0.53) | MEN1KMT2AOPRM1CCR5HTT | |
| SCHEMBL4132155 | 0.78 | SLC6A2 (0.60) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL4198203 | 0.77 | OPRM1 (0.62) | MEN1KMT2ACTSDOPRM1CCR5 | |
| SCHEMBL2421731 | 0.76 | CTSD (0.56) | MEN1KMT2ACTSDOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124635-A1 | CHEMICAL COMPOUNDS | PFIZER INC. (GB) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124635-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR3, CCR2 | MEN1 3241/4885KMT2A 3004/4885CTSD 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.